490 related articles for article (PubMed ID: 29275868)
1. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
Pagliara MM; Tagliaferri L; Azario L; Lenkowicz J; Lanza A; Autorino R; Caputo CG; Gambacorta MA; Valentini V; Blasi MA
Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868
[TBL] [Abstract][Full Text] [Related]
2. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.
Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
Br J Ophthalmol; 1996 Aug; 80(8):732-9. PubMed ID: 8949719
[TBL] [Abstract][Full Text] [Related]
3. Ocular complications after iodine brachytherapy for large uveal melanomas.
Puusaari I; Heikkonen J; Kivelä T
Ophthalmology; 2004 Sep; 111(9):1768-77. PubMed ID: 15350335
[TBL] [Abstract][Full Text] [Related]
4. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
Puusaari I; Heikkonen J; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
[TBL] [Abstract][Full Text] [Related]
5. Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.
Tarmann L; Wackernagel W; Ivastinovic D; Schneider M; Winkler P; Langmann G
PLoS One; 2017; 12(8):e0183833. PubMed ID: 28859118
[TBL] [Abstract][Full Text] [Related]
6. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.
Shields CL; Naseripour M; Cater J; Shields JA; Demirci H; Youseff A; Freire J
Ophthalmology; 2002 Oct; 109(10):1838-49. PubMed ID: 12359604
[TBL] [Abstract][Full Text] [Related]
7. Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma.
Bianciotto C; Shields CL; Pirondini C; Mashayekhi A; Furuta M; Shields JA
Ophthalmology; 2010 May; 117(5):1005-12. PubMed ID: 20079924
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review.
Le BHA; Kim JW; Deng H; Rayess N; Jennelle RL; Zhou SY; Astrahan MA; Berry JL
Brachytherapy; 2018; 17(6):981-989. PubMed ID: 30082188
[TBL] [Abstract][Full Text] [Related]
9. Factors predictive of radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma.
Krema H; Xu W; Payne D; Vasquez LM; Pavlin CJ; Simpson R
Can J Ophthalmol; 2011 Apr; 46(2):158-63. PubMed ID: 21708084
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience.
Perri P; Fiorica F; D'Angelo S; Lamberti G; Parmeggiani F; Martini A; Carpenteri F; Colosimo C; Micucci M; Perazzini L; De Gugliemo E; Berretta M; Sebastiani A; Cartei F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1919-24. PubMed ID: 23242717
[TBL] [Abstract][Full Text] [Related]
11. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.
Shields CL; Shields JA; Cater J; Gündüz K; Miyamoto C; Micaily B; Brady LW
Arch Ophthalmol; 2000 Sep; 118(9):1219-28. PubMed ID: 10980767
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
13. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
14. Vision Loss Following Episcleral Brachytherapy for Uveal Melanoma: Development of a Vision Prognostication Tool.
Aziz HA; Singh N; Bena J; Wilkinson A; Singh AD
JAMA Ophthalmol; 2016 Jun; 134(6):615-20. PubMed ID: 27101414
[TBL] [Abstract][Full Text] [Related]
15. Retina dose as a predictor for visual acuity loss in
Heilemann G; Fetty L; Blaickner M; Nesvacil N; Zehetmayer M; Georg D; Dunavoelgyi R
Radiother Oncol; 2018 Jun; 127(3):379-384. PubMed ID: 29452902
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy.
Badiyan SN; Rao RC; Apicelli AJ; Acharya S; Verma V; Garsa AA; DeWees T; Speirs CK; Garcia-Ramirez J; Esthappan J; Grigsby PW; Harbour JW
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):801-5. PubMed ID: 24462385
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
18. [The analysis of I125 brachytherapy complications in cases of uveal melanoma].
Pogrzebielski A; Starzycka M; Romanowska-Dixon B; Jakubowska B; Szpakowicz U
Klin Oczna; 2005; 107(1-3):49-53. PubMed ID: 16052800
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma.
Krema H; Heydarian M; Beiki-Ardakani A; Weisbrod D; Xu W; Laperriere NJ; Sahgal A
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):510-5. PubMed ID: 23507292
[TBL] [Abstract][Full Text] [Related]
20. Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma.
Yousef YA; Finger PT
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1107-12. PubMed ID: 22172910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
